The enhanced delivery of salinomycin to CD133+ ovarian cancer stem cells through CD133 antibody conjugation with poly(lactic-co-glycolic acid)-poly(ethylene glycol) nanoparticles

Mi,Yi; Huang,Yuqin; Deng,Jie

doi:10.3892/ol.2018.8140

The enhanced delivery of salinomycin to CD133+ ovarian cancer stem cells through CD133 antibody conjugation with poly(lactic-co-glycolic acid)-poly(ethylene glycol) nanoparticles

Authors:
- Yi Mi
- Yuqin Huang
- Jie Deng
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Xiangyang No.1 People's Hospital, Hubei University of Medicine, Xiangyang, Hubei 441000, P.R. China
Published online on: March 1, 2018 https://doi.org/10.3892/ol.2018.8140
Pages: 6611-6621

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ovarian cancer is the most lethal gynecologic malignancy, and ovarian cancer stem cells (CSCs) serve a pivotal function in the metastasis and recurrence of ovarian cancer. Multiple previous studies have validated CD133 as a marker of ovarian CSCs. Although salinomycin is a promising therapeutic agent that has been demonstrated to kill CSCs in various types of cancer, poor aqueous solubility hampers its clinical application. The present study used salinomycin‑loaded poly(lactic‑co‑glycolic acid)‑poly(ethylene glycol) nanoparticles conjugated with CD133 antibodies (CD133‑SAL‑NP) to eliminate CD133+ ovarian CSCs. The results revealed that CD133‑SAL‑NPs were of an appropriate size (149.2 nm) and exhibited sustained drug release. CD133‑SAL‑NPs efficiently bound to CD133+ ovarian cancer cells, resulting in an increased cytotoxic effect in CD133+ ovarian cancer cells, compared with the untargeted SAL‑NPs and salinomycin. CD133‑SAL‑NPs reduced the percentage of CD133+ ovarian CSCs in ovarian cells more effectively than treatment with salinomycin or SAL‑NPs, suggesting that CD133‑SAL‑NP targeted CD133+ ovarian CSCs. In nude mice bearing ovarian cancer xenografts, CD133‑SAL‑NPs exerted improved therapeutic effects compared with SAL‑NPs and salinomycin. Thus, CD133 was demonstrated to be a promising target for drug delivery to ovarian CSCs, and may be useful as an agent to inhibit the growth of ovarian cancer by targeting CD133+ ovarian CSCs. CD133‑SAL‑NPs may therefore represent a promising approach for the treatment of ovarian cancer.

View Figures

View References

1	Baba T, Convery PA, Matsumura N, Whitaker RS, Kondoh E, Perry T, Huang Z, Bentley RC, Mori S, Fujii S, et al: Epigenetic regulation of CD133 and tumorigenicity of CD133⁺ ovarian cancer cells. Oncogene. 28:209–218. 2009. View Article : Google Scholar : PubMed/NCBI
2	Zhou BB, Zhang H, Damelin M, Geles KG, Grindley JC and Dirks PB: Tumour-initiating cells: Challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov. 8:806–823. 2009. View Article : Google Scholar : PubMed/NCBI
3	Zeimet AG, Reimer D, Sopper S, Boesch M, Martowicz A, Roessler J, Wiedemair AM, Rumpold H, Untergasser G, Concin N, et al: Ovarian cancer stem cells. Neoplasma. 59:747–755. 2012. View Article : Google Scholar : PubMed/NCBI
4	Siclari VA and Qin L: Targeting the osteosarcoma cancer stem cell. J Orthop Surg Res. 5:782010. View Article : Google Scholar : PubMed/NCBI
5	Gao J, Li W, Guo Y and Feng SS: Nanomedicine strategies for sustained, controlled and targeted treatment of cancer stem cells. Nanomedicine (Lond). 11:3261–3282. 2016. View Article : Google Scholar : PubMed/NCBI
6	Xie FY, Xu WH, Yin C, Zhang GQ, Zhong YQ and Gao J: Nanomedicine strategies for sustained, controlled, and targeted treatment of cancer stem cells of the digestive system. World J Gastrointest Oncol. 8:735–744. 2016. View Article : Google Scholar : PubMed/NCBI
7	Shah MM and Landen CN: Ovarian cancer stem cells: Are they real and why are they important? Gynecol Oncol. 132:483–489. 2014. View Article : Google Scholar : PubMed/NCBI
8	Lupia M and Cavallaro U: Ovarian cancer stem cells: Still an elusive entity? Mol Cancer. 16:642017. View Article : Google Scholar : PubMed/NCBI
9	Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA and Lander ES: Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell. 21:645–659. 2009. View Article : Google Scholar
10	Yue W, Hamaï A, Tonelli G, Bauvy C, Nicolas V, Tharinger H, Codogno P and Mehrpour M: Inhibition of the autophagic flux by salinomycin in breast cancer stem-like/progenitor cells interferes with their maintenance. Autophagy. 9:714–729. 2013. View Article : Google Scholar : PubMed/NCBI
11	Gong Z, Chen D, Xie F, Liu J, Zhang H, Zou H, Yu Y, Chen Y, Sun Z, Wang X, et al: Codelivery of salinomycin and doxorubicin using nanoliposomes for targeting both liver cancer cells and cancer stem cells. Nanomedicine (Lond). 11:2565–2579. 2016. View Article : Google Scholar : PubMed/NCBI
12	Xie F, Zhang S, Liu J, Gong Z, Yang K, Zhang H, Lu Y, Zou H, Yu Y, Chen Y, et al: Codelivery of salinomycin and chloroquine by liposomes enables synergistic antitumor activity in vitro. Nanomedicine (Lond). 11:1831–1846. 2016. View Article : Google Scholar : PubMed/NCBI
13	Zhang Y, Zhang H, Wang X, Wang J, Zhang X and Zhang Q: The eradication of breast cancer and cancer stem cells using octreotide modified paclitaxel active targeting micelles and salinomycin passive targeting micelles. Biomaterials. 33:679–691. 2012. View Article : Google Scholar : PubMed/NCBI
14	Zhao P, Dong S, Bhattacharyya J and Chen M: iTEP nanoparticle-delivered salinomycin displays an enhanced toxicity to cancer stem cells in orthotopic breast tumors. Mol Pharm. 11:2703–2712. 2014. View Article : Google Scholar : PubMed/NCBI
15	Guo J, Gao X, Su L, Xia H, Gu G, Pang Z, Jiang X, Yao L, Chen J and Chen H: Aptamer-functionalized PEG-PLGA nanoparticles for enhanced anti-glioma drug delivery. Biomaterials. 32:8010–8020. 2011. View Article : Google Scholar : PubMed/NCBI
16	Chen H, Gao J, Lu Y, Kou G, Zhang H, Fan L, Sun Z, Guo Y and Zhong Y: Preparation and characterization of PE38KDEL-loaded anti-HER2 nanoparticles for targeted cancer therapy. J Control Release. 128:209–216. 2008. View Article : Google Scholar : PubMed/NCBI
17	Manjappa AS, Chaudhari KR, Venkataraju MP, Dantuluri P, Nanda B, Sidda C, Sawant KK and Murthy RS: Antibody derivatization and conjugation strategies: Application in preparation of stealth immunoliposome to target chemotherapeutics to tumor. J Control Release. 150:2–22. 2011. View Article : Google Scholar : PubMed/NCBI
18	Gao J, Liu W, Xia Y, Li W, Sun J, Chen H, Li B, Zhang D, Qian W, Meng Y, et al: The promotion of siRNA delivery to breast cancer overexpressing epidermal growth factor receptor through anti-EGFR antibody conjugation by immunoliposomes. Biomaterials. 32:3459–3470. 2011. View Article : Google Scholar : PubMed/NCBI
19	Gao J, Sun J, Li H, Liu W, Zhang Y, Li B, Qian W, Wang H, Chen J and Guo Y: Lyophilized HER2-specific PEGylated immunoliposomes for active siRNA gene silencing. Biomaterials. 31:2655–2664. 2010. View Article : Google Scholar : PubMed/NCBI
20	Nagy I, Caelers A, Monge A, Bonabi S, Huber AM and Bodmer D: NF-kappaB-dependent apoptotic hair cell death in the auditory system. Audiol Neurotol. 12:209–220. 2007. View Article : Google Scholar
21	Gao J, Yu Y, Zhang Y, Song J, Chen H, Li W, Qian W, Deng L, Kou G, Chen J and Guo Y: EGFR-specific PEGylated immunoliposomes for active siRNA delivery in hepatocellular carcinoma. Biomaterials. 33:270–282. 2012. View Article : Google Scholar : PubMed/NCBI
22	Kumari A, Yadav SK and Yadav SC: Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces. 75:1–18. 2010. View Article : Google Scholar : PubMed/NCBI
23	Green MR, Manikhas GM, Orlov S, Afanasyev B, Makhson AM, Bhar P and Hawkins MJ: Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann Oncol. 17:1263–1268. 2006. View Article : Google Scholar : PubMed/NCBI
24	Chumsri S and Burger AM: Cancer stem cell targeted agents: Therapeutic approaches and consequences. Curr Opin Mol Ther. 10:323–333. 2008.PubMed/NCBI
25	Gao J, Chen H, Yu Y, Song J, Song H, Su X, Li W, Tong X, Qian W, Wang H, et al: Inhibition of hepatocellular carcinoma growth using immunoliposomes for co-delivery of adriamycin and ribonucleotide reductase M2 siRNA. Biomaterials. 34:10084–10098. 2013. View Article : Google Scholar : PubMed/NCBI
26	Wang CH, Chiou SH, Chou CP, Chen YC, Huang YJ and Peng CA: Photothermolysis of glioblastoma stem-like cells targeted by carbon nanotubes conjugated with CD133 monoclonal antibody. Nanomedicine. 7:69–79. 2011. View Article : Google Scholar : PubMed/NCBI
27	Shvedova AA and Kagan VE: The role of nanotoxicology in realizing the ‘helping without harm’ paradigm of nanomedicine: Lessons from studies of pulmonary effects of single-walled carbon nanotubes. J Intern Med. 267:106–118. 2010. View Article : Google Scholar : PubMed/NCBI
28	Visvader JE and Lindeman GJ: Cancer stem cells: Current status and evolving complexities. Cell Stem Cell. 10:717–728. 2012. View Article : Google Scholar : PubMed/NCBI
29	Chaffer CL, Marjanovic ND, Lee T, Bell G, Kleer CG, Reinhardt F, D'Alessio AC, Young RA and Weinberg RA: Poised chromatin at the ZEB1 promoter enables breast cancer cell plasticity and enhances tumorigenicity. Cell. 154:61–74. 2013. View Article : Google Scholar : PubMed/NCBI